Get the Stockscreener App
35.17
0.80%
0.28
After Hours:
35.17
Qiagen Nv stock is traded at $35.17, with a volume of 1.19M.
It is up +0.80% in the last 24 hours and down -12.01% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$34.89
Open:
$35.01
24h Volume:
1.19M
Relative Volume:
0.59
Market Cap:
$7.25B
Revenue:
$2.09B
Net Income/Loss:
$424.88M
P/E Ratio:
17.21
EPS:
2.0439
Net Cash Flow:
$447.20M
1W Performance:
+6.64%
1M Performance:
-12.01%
6M Performance:
-24.91%
1Y Performance:
-16.90%
1-Day Range:
$34.96
$35.43
1-Week Range:
$32.94
$35.43
52-Week Range:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
35.17 | 7.20B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen N.V. (QGEN) Stock Analysis: Evaluating The 24.59% Potential Upside - DirectorsTalk Interviews
Qiagen N.V. stock (NL0012169213): Jefferies trims target while shares edge higher - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Jefferies cuts target as diagnostics group navigates post-pandemic - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): oncology ramp and new diagnostics deals put focus on growth mix - AD HOC NEWS
Release according to Article 40, Section 1 of the WpHG - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. stock (NL0012169213): Legal probes and price drop unsettle investors - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Diagnostics group updates investors after solid Q1 2026 - AD HOC NEWS
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
Qiagen N.V. Stock 12‑Month Price Target Cut to $42.04, Implies 20% Upside - TradingView
Qiagen stock (NL0012169213): Shares rise after Q1 update and guidance reaffirmation - AD HOC NEWS
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform - TradingView
Qiagen N.V. stock (NL0012169213): Outlook raised after Q1 2026 update and new AI assistant launch - AD HOC NEWS
QIAGEN NV cuts FY outlook despite in-line prelim Q1 EPS - MSN
QIAGEN Discloses Million-Dollar Insider Share Purchase by Supervisory Board Member Trust - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen launches AI assistant for laboratory research By Investing.com - Investing.com South Africa
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows - BioSpace
Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Qiagen stock (NL0012169213): Q1 update and share-price backdrop - AD HOC NEWS
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflo - PharmiWeb.com
Qiagen launches AI assistant for laboratory research - Investing.com
New QIAGEN AI lab assistant is designed to speed experiment planning - Stock Titan
QIAGEN launches AI assistant for laboratory workflow support - StreetInsider
Qiagen N.V. stock (NL0012169213): Diagnostics group lifts 2026 outlook after first?quarter earnings - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): steady earnings backdrop as shares lag 2026 highs - AD HOC NEWS
Qiagen (QGEN) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
3 Stocks in Focus That Recently Declared Dividend Hikes Amid High Inflation - TradingView
QIAGEN and NVIDIA partner on AI drug discovery - Yahoo Finance
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA - BioSpace
Qiagen stock (NL0012169213): Q1 update keeps diagnostics and life-science demand in focus - AD HOC NEWS
QIAGEN partners with NVIDIA on AI drug discovery platform By Investing.com - Investing.com Nigeria
QIAGEN partners with NVIDIA on AI drug discovery platform - Investing.com UK
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V. - Business Wire
QIAGEN partners with NVIDIA to integrate AI into drug discovery platform - StreetInsider
Bank of America Discloses 2.98% Stake in Qiagen via AFM Filing - The Globe and Mail
Qiagen's Digital Insights Business to Integrate Nvidia's BioNeMo Platform - marketscreener.com
Qiagen discloses AFM notification on 2.99% Bank of America stake - TipRanks
Qiagen N.V. stock (NL0012169213): earnings outlook and molecular diagnostics focus - AD HOC NEWS
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $36 - Moomoo
Citigroup downgrades Qiagen NV (QGEN) - MSN
Qiagen N.V. stock (NL0012169213): diagnostics specialist updates investors after Q1 results - AD HOC NEWS
QGEN Maintained by Stifel -- Price Target Lowered to $36 - GuruFocus
Qiagen stock (NL0012169213): New strategic tie-up puts diagnostics in focus - AD HOC NEWS
Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Stifel cuts Qiagen stock price target to $36 on weaker outlook By Investing.com - Investing.com Australia
Qiagen stock (NL0012169213): QIAGEN’s U.S. diagnostics exposure stays in focus - AD HOC NEWS
Stifel cuts Qiagen stock price target to $36 on weaker outlook - Investing.com Australia
Qiagen NV (QGEN) PT Lowered to $36 at Stifel on 'Lower Growth Outlook' - StreetInsider
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Cuts Target Price to $36 - Moomoo
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):